Latest news with #Tempus'
Business Insider
2 days ago
- Business
- Business Insider
Tempus AI announces launch of its Fuses program
Tempus AI (TEM) announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Confident Investing Starts Here:
Business Wire
3 days ago
- Business
- Business Wire
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. 'We have spent the last ten years building, scaling, and curating one of the most comprehensive datasets in our industry, and now we are well positioned to develop the world's largest diagnostic model, designed to answer critical, unsolved questions and make our diagnostics smarter and more personalized,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We are on the brink of delivering tangible, transformative change in matching the right therapies to the right patients - making personalized care a reality for millions.' The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Fuses and its insights in oncology clinical care and therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Associated Press
5 days ago
- Business
- Associated Press
Wolf Popper LLP Announces Investigation on Behalf of Tempus AI, Inc. Investors
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ('Tempus') common stock (NASDAQ: TEM). Tempus uses AI to provide medical solutions to physicians. Before the market opened on May 28, 2025, Spruce Point Capital Management published a report entitled The Tempest Surrounding Tempus AI. The report discussed 1) Tempus' CEO and a large Tempus shareholder have been associated with several companies that have either gone bankrupt or have done very poorly as public companies, 2) several Tempus board members and Tempus' Chief Accounting Officer have been connected to companies that had to restate their financials, 3) potential financial irregularities and related party issues, 4) whether Tempus' technology actually works, and 5) the selling of Tempus shares by insiders. On this news, Tempus' stock price fell $12.67 per share to $53.20 on May 28, 2025, down 19.2% on very heavy volume. Investors who lost over $50,000 trading in Tempus common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or [email protected]. Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper's reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm's website at May Be Considered Attorney Advertising in Certain Jurisdictions. Prior Results Do Not Guarantee a Similar Outcome. Wolf Popper LLP Adam Savett 845 Third Avenue New York, NY 10022 Tel.: (212) 451-9655 Email: [email protected]
Yahoo
19-05-2025
- Business
- Yahoo
Should You be Confident in Tempus AI (TEM)?
Baron Funds, an investment management company, released its 'Baron Discovery Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due to Trump's serious tariff enactment, which the market perceives as inflationary and slowing economic growth. The decline accelerated after April 2nd, causing fears of a trade war and global recession. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM) . Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company. The one-month return of Tempus AI, Inc. (NASDAQ:TEM) was 59.81%, and YTD its shares gained 93.99% of their value. On May 16, 2025, Tempus AI, Inc. (NASDAQ:TEM) stock closed at $65.49 per share with a market capitalization of $11.337 billion. Baron Discovery Fund stated the following regarding Tempus AI, Inc. (NASDAQ:TEM) in its Q1 2025 investor letter: "Tempus AI, Inc. (NASDAQ:TEM). is an intelligent diagnostics and health care data company with two synergistic business units: Genomics and Data. Although shares have been volatile since its June 2024 IPO, we attribute these fluctuations to trading dynamics that do not reflect Tempus' business fundamentals and have managed our position size accordingly, which was a key reason for the investment's contribution this quarter. In the long run, we expect the company's Genomics business (diagnostics for cancer treatment selection) to continue to grow rapidly as the market develops. The data generated from Tempus' diagnostic tests also enhances its Data business, as Tempus combines its genomics data with clinical patient data from its oncology partners, to generate an enormous proprietary multimodal dataset. We believe that no one will be able to replicate the breadth and depth of this dataset, given Tempus' enormous proprietary advantages. Tempus licenses its dataset to biopharmaceutical companies for use in designing smarter clinical trials and for identifying new drug targets." A technician working with genomic sequencing equipment. Tempus AI, Inc. (NASDAQ:TEM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Tempus AI, Inc. (NASDAQ:TEM) at the end of the fourth quarter, compared to 7 in the third quarter. In the first quarter of 2025, Tempus AI, Inc.'s (NASDAQ:TEM) revenue increased 75.4% year-over-year to $255.7 million. While we acknowledge the potential of Tempus AI, Inc. (NASDAQ:TEM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Tempus AI, Inc. (NASDAQ:TEM) and shared the list of best performing healthcare stocks to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Should You be Confident in Tempus AI (TEM)?
Baron Funds, an investment management company, released its 'Baron Discovery Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due to Trump's serious tariff enactment, which the market perceives as inflationary and slowing economic growth. The decline accelerated after April 2nd, causing fears of a trade war and global recession. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM) . Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company. The one-month return of Tempus AI, Inc. (NASDAQ:TEM) was 59.81%, and YTD its shares gained 93.99% of their value. On May 16, 2025, Tempus AI, Inc. (NASDAQ:TEM) stock closed at $65.49 per share with a market capitalization of $11.337 billion. Baron Discovery Fund stated the following regarding Tempus AI, Inc. (NASDAQ:TEM) in its Q1 2025 investor letter: "Tempus AI, Inc. (NASDAQ:TEM). is an intelligent diagnostics and health care data company with two synergistic business units: Genomics and Data. Although shares have been volatile since its June 2024 IPO, we attribute these fluctuations to trading dynamics that do not reflect Tempus' business fundamentals and have managed our position size accordingly, which was a key reason for the investment's contribution this quarter. In the long run, we expect the company's Genomics business (diagnostics for cancer treatment selection) to continue to grow rapidly as the market develops. The data generated from Tempus' diagnostic tests also enhances its Data business, as Tempus combines its genomics data with clinical patient data from its oncology partners, to generate an enormous proprietary multimodal dataset. We believe that no one will be able to replicate the breadth and depth of this dataset, given Tempus' enormous proprietary advantages. Tempus licenses its dataset to biopharmaceutical companies for use in designing smarter clinical trials and for identifying new drug targets." A technician working with genomic sequencing equipment. Tempus AI, Inc. (NASDAQ:TEM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Tempus AI, Inc. (NASDAQ:TEM) at the end of the fourth quarter, compared to 7 in the third quarter. In the first quarter of 2025, Tempus AI, Inc.'s (NASDAQ:TEM) revenue increased 75.4% year-over-year to $255.7 million. While we acknowledge the potential of Tempus AI, Inc. (NASDAQ:TEM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Tempus AI, Inc. (NASDAQ:TEM) and shared the list of best performing healthcare stocks to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
